Article Text

AB0125 The Effect of Gv1001, A Peptide Vaccine, in Animal Model of Rheumatoid Arthritis
  1. I.A. Choi1,
  2. J.Y. Choi2,
  3. J.S. Kim2,
  4. S.-Y. Oh3,
  5. S. Kim3,
  6. E.Y. Lee2
  1. 1Division of Rheumatology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju
  2. 2Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul
  3. 3KAEL-GemVax Co., Ltd, Seongnam, Korea, Republic Of


Background GV1001 is a 16-mer peptide developed as a cancer vaccine to prime the immune system to recognize telomerase. Besides its role as a cancer vaccine, GV1001 has anti-inflammatory effects in in-vitro experiments using macrophage or monocyte.

Objectives We evaluated the effect of GV1001 to inhibit joint inflammation in animal model of RA.

Methods 5-week old BDA/1 mice were used to induce collagen induced arthritis (CIA). Mice were immunized with bovine type II collagen on day 1 and boosted on day 21. Treatments with GV1001 (0.2 nM, 1 nM, 2 nM, 5 nM, and 10 nM) or placebo were started on day 21, three times in alternative week (on day 21, 23, 25 and day 35, 37, 39). Weight and arthritis index of the mice using a standardized grading scale (0–3) were monitored from day 21. Observation finished on day 42, harvesting mouse serum and joints for further analysis. Histological scores of joint damage were assessed using 0–3 grading scale.

Results Mean arthritis index on day 42 was lower in 0.2 nM GV1001 group compared to placebo group without statistical significance (p=0.1). Histologic assessment after low dose GV1001 treatment showed a tendency to have a lower histologic score (Fig. 1). Serum IL-6 level was significantly lower in 1 nM (the same concentration used as human cancer vaccine) and 0.2 nM GV1001 group (p<0.01, both) compared to placebo group.

Figure 1.

Representative histology of naïve mouse (A), CIA mice treated with placebo (B) and 0.2 nM GV1001 (C), H&E, 100x.

Conclusions In this study, we explored the novel therapeutic effect of GV1001 in animal model of rheumatoid arthritis. Protective effect of GV1001 was not dose dependent and effective in 1 nM, which is the same concentration used as human cancer vaccine and the lower dose as 0.2 nM. These results suggest the therapeutic potential of GV1001 as a new RA treatment.

Disclosure of Interest I. A. Choi: None declared, J. Y. Choi: None declared, J. S. Kim: None declared, S.-Y. Oh Employee of: KAEL-GemVax, developer of GV1001, S. Kim Shareholder of: KAEL-GemVax, developer of GV1001, E. Y. Lee: None declared

DOI 10.1136/annrheumdis-2014-eular.2421

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.